Avidity Biosciences
10578 Science Center Drive
Suite 125
San Diego
California
92121
United States
Tel: 858-401-7900
Website: http://www.aviditybiosciences.com/
Email: info@aviditybio.com
About Avidity Biosciences
Our vision is to profoundly improve people’s lives by revolutionizing the delivery of RNA therapeutics. We’re utilizing our proprietary AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) with the precision of oligonucleotide-based therapies in order to redefine RNA therapeutics and more effectively target underlying genetic drivers of diseases. We are delivering on this vision by investing in our platform, our pipeline and our people.
Our commitment to rigorous and innovative science is matched only by our passion to see patients’ lives changed. We consistently challenge ourselves to Be AVID – Agile, Visionary, Integrated and Diverse.
We are assembling a diverse team experienced in rare disease and RNA therapies. Our team members bring expertise in research, development and commercial execution. We are focused on cultivating the right team to not only grow the company, but also to reflect the communities we serve. We are dedicated to employing and retaining a diverse and inclusive workforce at all levels of the organization to not only ensure that different backgrounds and perspectives are being heard and acted upon, but that our employees also feel understood, accepted and valued.
BeAVID
131 articles about Avidity Biosciences
-
Avidity Biosciences to Host Investor and Analyst Event Focused on AOC 1001 Topline Data from Phase 1/2 MARINA™ Trial on April 27, 2023
4/13/2023
Avidity Biosciences, Inc. today announced that the company will host Volume 7 of its investor and analyst series focused on the topline safety, biomarker and functional data from the AOC 1001 Phase 1/2 MARINA™ trial in adults with myotonic dystrophy type 1 (DM1) on April 27, 2023 at 5:30 p.m. ET in Boston and available via webcast.
-
Avidity Biosciences Provides Regulatory Update on AOC 1001 for Myotonic Dystrophy Type 1 and Plans to Present Top-line Data from Phase 1/2 MARINA™ Trial at AAN Annual Meeting
3/30/2023
Avidity Biosciences, Inc. (Nasdaq: RNA) today provided an update on the Phase 1/2 MARINA™ trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1), an underrecognized, progressive and often fatal neuromuscular disease with no approved treatment options.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - March 21, 2023
3/21/2023
Avidity Biosciences, Inc. announced that on March 20, 2023, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 73,700 shares of its common stock and 36,850 restricted stock units to six new non-executive employees under the Avidity Biosciences, Inc.
-
Avidity Biosciences Announces Upcoming Presentations at 2023 MDA Clinical & Scientific Conference
3/13/2023
Avidity Biosciences, Inc. today announced that the company will be presenting two oral presentations and multiple poster presentations at the 2023 MDA Clinical & Scientific Conference in Dallas, Texas, being held March 19-22, 2023.
-
Avidity Biosciences to Participate in Upcoming March 2023 Investor Conference
3/1/2023
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following conference.
-
Avidity Biosciences Reports Fourth Quarter and Year-End 2022 Financial Results and Recent Highlights
2/28/2023
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today reported financial results for the fourth quarter and year ended December 31, 2022 and highlighted recent corporate progress.
-
Avidity Biosciences Announces Arthur A. Levin to Join Board of Directors and Transition to Distinguished Scientist and Strategic Leader
2/23/2023
Avidity Biosciences, Inc. today announced that Arthur A. Levin , Ph.D. has been appointed to the board.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - February 22, 2023
2/22/2023
Avidity Biosciences, Inc. announced that on February 20, 2023, the Compensation Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 27,400 shares of its common stock and 13,700 restricted stock units to three new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan.
-
Avidity Biosciences Receives FDA Orphan Drug Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
2/14/2023
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
-
Avidity Biosciences to Participate in Upcoming Investor Conference - February 07, 2023
2/7/2023
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that Avidity management will be participating at the following conference.
-
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Jan 20, 2023
1/20/2023
Avidity Biosciences, Inc. announced that on January 20, 2023, the Compensation Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 12,350 shares of its common stock and 6,175 restricted stock units to three new non-executive employees under the Avidity Biosciences, Inc.
-
Avidity Biosciences Granted FDA Fast Track Designation for AOC 1020 for the Treatment of Facioscapulohumeral Muscular Dystrophy
1/18/2023
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AOC 1020 for the treatment of facioscapulohumeral muscular dystrophy (FSHD).
-
Avidity Biosciences, Inc. Announces Pricing of Upsized Public Offering of Common Stock - December 16, 2022
12/16/2022
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced the pricing of an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.25 per share.
-
Avidity Biosciences, Inc. Announces Proposed Public Offering of Common Stock
12/15/2022
Avidity Biosciences, Inc. today announced that it intends to offer and sell, subject to market and other conditions, $150 million of shares of its common stock.
-
Shares of Avidity Biosciences are soaring following reported early signs of clinical activity and improvement in patients with myotonic dystrophy type 1 (DM1) treated with its RNA-based therapeutic.
-
Avidity Announces Positive AOC 1001 Phase 1/2 MARINA™ Data Demonstrating First-Ever Successful Targeted Delivery of RNA to Muscle - Revolutionary Advancement for the Field of RNA Therapeutics
12/14/2022
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced positive AOC 1001 data from the preliminary assessment of the Phase 1/2 MARINA™ trial demonstrating the first-ever successful targeted delivery of RNA into muscle, a revolutionary advancement for the field of RNA therapeutics.
-
Avidity Biosciences Reports Third Quarter 2022 Financial Results and Recent Highlights
11/8/2022
Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress.
-
Avidity Biosciences to Participate in Upcoming November 2022 Investor Conferences
11/1/2022
Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates, announced that the Avidity management team will be participating at the following upcoming conferences:
-
Avidity Biosciences Announces Phase 1/2 EXPLORE44™ Trial of AOC 1044 for Duchenne Muscular Dystrophy Mutations Amenable to Exon 44 Skipping
10/11/2022
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced the Phase 1/2 EXPLORE44™ clinical trial of AOC 1044 in healthy volunteers and participants with Duchenne muscular dystrophy (DMD), a rare, genetic condition that is characterized by progressive muscle damage and weakness.
-
Avidity Biosciences Announces Upcoming Presentations at 27th International Hybrid Annual Congress of World Muscle Society
10/6/2022
Avidity Biosciences, Inc. (Nasdaq: RNA) today announced the company will be presenting five poster presentations including the MARINA™ study design for myotonic dystrophy type 1 and preclinical and real-world data from the facioscapulohumeral muscular dystrophy (FSHD) and Duchenne muscular dystrophy (DMD) programs.